Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study

• Main Authors: Melinda Gooderham (Author), Emma Guttman-Yassky (Author), Ken Igawa (Author), Kenji Kabashima (Author), Ehsanollah Esfandiari (Author), Angela J. Rylands (Author), Angela Williams (Author), Annabel Nixon (Author), Jennifer E. Dent (Author), Eric Simpson (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden...